RetinalGenix Technologies (RTGN) Cash from Financing Activities (2020 - 2026)
RetinalGenix Technologies (RTGN) posted Cash from Financing Activities of $94619.0 for Q1 2026, down 33.79% sequentially from $142901.0 in Q4 2025, and down 48.82% YoY from $184873.0 in Q1 2025.
RetinalGenix Technologies (RTGN) Cash from Financing Activities (2020 - 2026) Analysis & Trends
RetinalGenix Technologies has reported Cash from Financing Activities for 7 years, with the latest figure at $94619.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 48.82% year-over-year to $94619.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $476810.0 (down 33.65% YoY) and the FY2025 annual result came in at $567064.0, down 24.19% from the prior year.
- Cash from Financing Activities retreated to $94619.0 in Q1 2026 per RTGN's latest filing, from $142901.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $289981.0 in Q4 2023 and troughed at -$41618.0 in Q3 2023.
- A 5-year average of $120940.4 and a median of $113361.0 in 2024 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 1418.79% in 2023, down 166.22% in 2023.
- Over 5 years, Cash from Financing Activities stood at $29651.0 in 2022, then soared by 877.98% to $289981.0 in 2023, then plunged by 60.91% to $113361.0 in 2024, then advanced by 26.06% to $142901.0 in 2025, then plunged by 33.79% to $94619.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $94619.0, $142901.0, and $103090.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | -213.50 Mn |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - | 94,619.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94,619.00 |
| Mar 31, 2026 | 94,619.00 |
| Dec 31, 2025 | 142,901.00 |
| Dec 31, 2025 | 142,901.00 |
| Sep 30, 2025 | 103,090.00 |
| Sep 30, 2025 | 103,090.00 |
| Jun 30, 2025 | 136,200.00 |
| Jun 30, 2025 | 136,200.00 |
| Mar 31, 2025 | 184,873.00 |
| Mar 31, 2025 | 184,873.00 |
| Dec 31, 2024 | 113,361.00 |
| Dec 31, 2024 | 113,361.00 |
| Sep 30, 2024 | 239,108.00 |
| Sep 30, 2024 | 239,108.00 |
| Jun 30, 2024 | 181,322.00 |
| Jun 30, 2024 | 181,322.00 |
| Mar 31, 2024 | 214,205.00 |
| Mar 31, 2024 | 214,205.00 |
| Dec 31, 2023 | 289,981.00 |
| Dec 31, 2023 | 289,981.00 |